Latest filing published 22 Apr 2026 for Nasus Pharma Ltd, €9,315.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -6.5%Entry US$3.40 · Close 16 Oct 2026 US$3.18
- +35.3%Entry US$2.35 · Close 16 Oct 2026 US$3.18
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Dan Benjamin Teleman: trading record in brief
Dan Benjamin Teleman discloses dealings in Nasus Pharma Ltd to SEC (Form 4). Between 31 March 2026 and 22 April 2026, the trades on record add up to 2 filings.
No open-market sale appears; the market trades are 2 purchases worth €36k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
Most recently, on 22 April 2026, the filings show an open-market purchase worth €9,315 in Nasus Pharma Ltd. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Dan Benjamin Teleman
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 2,900 shares@ US$3.7626.1% of flowOrdinary SharesSEC:0001493152-26-018607:0Canonical exit: 21 Jul 2026 (T+90)
- 15,000 shares@ US$2.0473.9% of flowOrdinary SharesSEC:0001493152-26-014503:0Canonical exit: 29 Jun 2026 (T+90)
2 of 2 declarations